bupropion and paroxetine

bupropion has been researched along with paroxetine in 78 studies

Research

Studies (78)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (7.69)18.2507
2000's34 (43.59)29.6817
2010's35 (44.87)24.3611
2020's3 (3.85)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J1
Ahman, M; Holmén, AG; Wan, H1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F1
Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Dalvie, D; Loi, CM; Smith, DA1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Preskorn, SH1
Liebowitz, MR; Marshall, RD1
DePalma, RL; Katholi, CR; Modell, JD; Modell, JG1
Grimes, JB; Hines, A; Labbate, LA; Pollack, MH1
Anand, VS; Dewan, MJ1
Roose, SP; Spatz, E1
Ascher, JA; Batey, SR; Donahue, RM; Houser, TL; Settle, EC; Weihs, KL1
Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL1
Dewan, V1
Klein, RM; Walker, JB; Yee, SL1
Bagby, RM; Kennedy, SH; Vanderkooy, JD1
Baker, GB; Kennedy, SH; Masellis, M; McCann, SM; McIntyre, RS; McKay, G; Raskin, J1
Asnis, GM; Gabbay, V; O'Dowd, MA1
Begley, AE; Joo, JH; Lenze, EJ; Mazumdar, S; Mulsant, BH; Pollock, BG; Reynolds, CF; Stack, JA; Weber, EM1
Bourin, M; Dailly, E; David, DJ; Hascoët, M; Ripoll, N1
DeVane, CL1
Nemeroff, CB1
Allen, MT; Girdler, SS; Golding, M; Light, KC; Straneva-Meuse, PA1
Altschuler, EL; Kast, RE1
Malik, AR; Ravasia, S; Wolf, PK1
Basinski, J; Begley, A; Dew, MA; Farhi, P; Mulsant, BH; Reynolds, CF; Whyte, EM1
Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E1
Chung, JY; Frank, L; Green, BL; Krupnick, J; Miranda, J; Prasad, M; Revicki, DA; Siddique, J1
Belin, T; Chung, J; Green, BL; Krupnick, JL; Miranda, J; Revicki, D; Siddique, J1
Bagby, RM; Cohen, NL; Fulton, KA; Greene, AL; Kennedy, SH; Rafi-Tari, S1
Edwards, JL1
Braun, M; Connemann, BJ; Freudenmann, RW; Schönfeldt-Lecuona, C; Wolf, RC1
Bensasi, S; Houck, PR; Lenze, EJ; Miller, MD; Mulsant, BH; Reynolds, CF; Stack, JA; Tew, JD; Whyte, EM1
Allen, MH; Bowden, CL; Calabrese, JR; Dennehy, EB; Fossey, MD; Friedman, ES; Gyulai, L; Hauser, P; Ketter, TA; Marangell, LB; Martinez, JM; Miklowitz, DJ; Nierenberg, AA; Ostacher, MJ; Otto, MW; Patel, J; Rapport, D; Sachs, GS; Thase, ME; Wisniewski, SR1
Dobkin, RD; Marin, H; Menza, MA1
Bensasi, S; Dew, MA; Houck, PR; Lenze, EJ; Mulsant, BH; Pollock, BG; Reynolds, CF; Stack, JA; Whyte, EM1
Silva, RR1
Gomeni, R; Merlo-Pich, E1
Guardia-Olmos, J; Gudayol-Ferré, E; Herrera-Abarca, J; Herrera-Guzmán, D; Herrera-Guzmán, I; Lira-Mandujano, J; Montoya-Pérez, K1
Billups, SJ; Delate, T; Dugan, D1
Bekkering, GE; Tuinier, S; Verbeeck, W1
Howland, RH1
LeBlanc, SR; Ovanessian, MM; Parikh, SV1
Abler, B; Grön, G; Hartmann, A; Metzger, C; Seeringer, A; Stingl, J; Walter, M1
Burke, AK; Duan, N; Ellis, SP; Grunebaum, MF; John Mann, J; Oquendo, MA1
Abler, B; Seeringer, A; Stingl, JC; Viviani, R1
Dhamee, MS; Gollapudy, S; Kumar, V1
Humpston, CS; Robinson, ES; Wood, CM1
Abler, B; Graf, H; Hartmann, A; Metzger, CD; Walter, M1
Campos, FL; Carvalho, MM; Coimbra, B; Lima, R; Pêgo, JM; Rodrigues, AJ; Rodrigues, C; Salgado, AJ; Sousa, N1
Bauer, N; Burke, AK; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Oquendo, MA; Sudol, K1
Bijlsma, EY; Chan, JS; Millan, MJ; Olivier, B; Oosting, RS; Veening, JG; Waldinger, MD1
Abler, B; Graf, H; Metzger, CD; Walter, M2
Blier, P; Chenu, F; El Iskandrani, KS; El Mansari, M; Manta, S; Oosterhof, C; Shim, S1
Burke, A; Gorlyn, M; Grunebaum, M; Keilp, J; Mann, JJ; Oquendo, M1
Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N1
Mimura, M; Mizushima, J; Nio, S; Suzuki, T; Tada, M; Uchida, H1
Buoli, M; Cahn, W; Serati, M1
Dudka, J; Poleszak, E; Serefko, A; Stasiuk, W; Świąder, K; Szopa, A; Wlaź, P; Wyska, E1
Burke, AK; Ellis, SP; Gorlyn, M; Grunebaum, MF; Keilp, JG; Mann, JJ; Oquendo, MA1
Burke, AK; Chaudhury, SR; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Metts, AV; Oquendo, MA; Parris, MS1
Carleton, BC; Etminan, M; Guo, MY; Kezouh, A; Kim, DD; Procyshyn, RM; Samii, A1
Carvalho, AF; Chaves Filho, AJM; de Sousa, FCF; Hyphantis, TN; Macêdo, D; McIntyre, RS; Menezes, CES; Quevedo, J; Vasconcelos, SMM1
Bulmus, O; Canpolat, S; Colakoglu, N; Kaya, N; Kelestimur, H; Ozcan, M; Ulker, N; Yardimci, A1
Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S1
Canpolat, S; Colakoglu, N; Kaya Tektemur, N; Kelestimur, H; Ozcan, M; Ulker, N; Yardimci, A1
Camino, S; Godoy, A; Smith, J; Strejilevich, SA; Szmulewicz, A1
Gedde-Dahl, A; Molden, E; Spigset, O1

Reviews

12 review(s) available for bupropion and paroxetine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
    The Journal of clinical psychiatry, 1995, Volume: 56 Suppl 6

    Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride

1995
Treatment of depression in patients with heart disease.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 20

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Comorbidity; Death, Sudden; Depressive Disorder; Double-Blind Method; Heart Block; Heart Diseases; Humans; Hypotension, Orthostatic; Myocardial Ischemia; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Risk Factors; Selective Serotonin Reuptake Inhibitors; Ventricular Fibrillation

1999
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.
    The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 18

    Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Delayed-Action Preparations; Drug Tolerance; Half-Life; Humans; Nausea; Paroxetine; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride

2003
Improving antidepressant adherence.
    The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 18

    Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Health Promotion; Humans; Paroxetine; Patient Compliance; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride

2003
Pharmacological treatments of pathological gambling.
    Journal of gambling studies, 2005,Spring, Volume: 21, Issue:1

    Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles

2005
Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review.
    Advances in therapy, 2009, Volume: 26, Issue:2

    Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Bupropion; Comorbidity; Desipramine; Evidence-Based Medicine; Humans; Lithium Carbonate; Monoamine Oxidase Inhibitors; Paroxetine; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2009
Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release?
    Pharmacology, biochemistry, and behavior, 2014, Volume: 121

    Topics: Animals; Antidepressive Agents; Aza Compounds; Brain; Bridged Bicyclo Compounds, Heterocyclic; Bupropion; Buspirone; Cyclohexanols; Disease Models, Animal; Dopamine; Female; Humans; Indoles; Male; Norepinephrine; Paroxetine; Pyridines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Synaptic Transmission; Venlafaxine Hydrochloride

2014
Antidepressant-related sexual dysfunction - perspectives from neuroimaging.
    Pharmacology, biochemistry, and behavior, 2014, Volume: 121

    Topics: Animals; Antidepressive Agents; Brain; Bupropion; Female; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Paroxetine; Psychopharmacology; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological

2014
Alternative pharmacological strategies for adult ADHD treatment: a systematic review.
    Expert review of neurotherapeutics, 2016, Volume: 16, Issue:2

    Topics: Adrenergic alpha-Agonists; Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Bupropion; Central Nervous System Stimulants; Desipramine; Dopamine Agents; Droxidopa; Drug Combinations; Duloxetine Hydrochloride; Guanfacine; Histamine Agents; Humans; Lisdexamfetamine Dimesylate; Lithium Compounds; Lobeline; Mecamylamine; Memantine; Modafinil; Morpholines; Nicotinic Agonists; Nicotinic Antagonists; Nomifensine; Paroxetine; Pyridines; Pyridoxine; Pyrrolidonecarboxylic Acid; Quinazolinones; Reboxetine; Venlafaxine Hydrochloride; Wakefulness-Promoting Agents

2016
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
    Journal of affective disorders, 2019, 05-01, Volume: 250

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride

2019
Are all antidepressants the same? The consumer has a point.
    Psychological medicine, 2023, Volume: 53, Issue:9

    Topics: Antidepressive Agents; Bupropion; Citalopram; Fluoxetine; Humans; Paroxetine; Sertraline; Venlafaxine Hydrochloride

2023

Trials

20 trial(s) available for bupropion and paroxetine

ArticleYear
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:3

    Topics: Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Bupropion; Comorbidity; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Risk Factors; Seizures; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2000
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Cytochrome P-450 CYP2D6; Dopamine Uptake Inhibitors; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride

2002
Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients.
    Journal of affective disorders, 2004, Volume: 79, Issue:1-3

    Topics: Adult; Antidepressive Agents, Second-Generation; Blood Pressure; Bupropion; Cross-Sectional Studies; Dose-Response Relationship, Drug; Epinephrine; Heart Rate; Humans; Hydrocortisone; Neurosecretory Systems; Paroxetine; Stress, Psychological

2004
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:12

    Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Lithium; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride

2004
Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.
    Archives of general psychiatry, 2005, Volume: 62, Issue:8

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Community Mental Health Services; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Costs; Female; Health Care Costs; Health Status; Humans; Minority Groups; Paroxetine; Poverty; Quality of Life; Referral and Consultation; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome

2005
One-year outcomes of a randomized clinical trial treating depression in low-income minority women.
    Journal of consulting and clinical psychology, 2006, Volume: 74, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Minority Groups; Paroxetine; Patient Education as Topic; Poverty; Psychotherapy, Group

2006
Sexual function during bupropion or paroxetine treatment of major depressive disorder.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2006, Volume: 51, Issue:4

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Distribution; Sexual Dysfunction, Physiological

2006
Impact of prior treatment exposure on response to antidepressant treatment in late life.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:11

    Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lithium Carbonate; Long-Term Care; Male; Nortriptyline; Paroxetine; Psychotherapy; Retreatment; Treatment Failure; Treatment Outcome

2006
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
    The New England journal of medicine, 2007, Apr-26, Volume: 356, Issue:17

    Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Bupropion; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Paroxetine; Treatment Outcome

2007
An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2

    Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Bupropion; Dizziness; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Pilot Projects; Piperazines; Quality of Life; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2007
Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2011, Volume: 36, Issue:9

    Topics: Adult; Antidepressive Agents; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Humans; Limbic System; Magnetic Resonance Imaging; Male; Neurons; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Young Adult

2011
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Pilot Projects; Selective Serotonin Reuptake Inhibitors; Suicidal Ideation; Suicide; Treatment Outcome

2012
Effect of paroxetine and bupropion on human resting brain perfusion: an arterial spin labeling study.
    NeuroImage, 2012, Jul-16, Volume: 61, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Bupropion; Cerebrovascular Circulation; Double-Blind Method; Humans; Male; Paroxetine; Spin Labels; Young Adult

2012
Modulation of attention network activation under antidepressant agents in healthy subjects.
    The international journal of neuropsychopharmacology, 2013, Volume: 16, Issue:6

    Topics: Adult; Analysis of Variance; Antidepressive Agents; Attention; Brain; Brain Mapping; Bupropion; Cross-Over Studies; Double-Blind Method; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Oxygen; Paroxetine; Photic Stimulation; Reaction Time; Surveys and Questionnaires; Young Adult

2013
SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.
    The Journal of clinical psychiatry, 2013, Volume: 74, Issue:9

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Psychometrics; Selective Serotonin Reuptake Inhibitors; Suicidal Ideation; Suicide, Attempted; Young Adult

2013
Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion.
    Psychiatry research, 2015, Feb-28, Volume: 225, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Suicidal Ideation; Suicide, Attempted; Treatment Outcome

2015
Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data.
    Journal of psychiatric research, 2015, Volume: 68

    Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Bupropion; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Treatment Outcome

2015
Serotonergic antidepressants decrease hedonic signals but leave learning signals in the nucleus accumbens unaffected.
    Neuroreport, 2016, Jan-06, Volume: 27, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Brain Mapping; Bupropion; Cross-Over Studies; Dopamine Uptake Inhibitors; Double-Blind Method; Erotica; Functional Laterality; Humans; Learning; Magnetic Resonance Imaging; Male; Motion Perception; Neuropsychological Tests; Nucleus Accumbens; Paroxetine; Reward; Selective Serotonin Reuptake Inhibitors; Sexual Behavior

2016
Suicidal ideation declines with improvement in the subjective symptoms of major depression.
    Journal of affective disorders, 2018, Volume: 227

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Suicidal Ideation; Treatment Outcome

2018
Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial.
    International clinical psychopharmacology, 2018, Volume: 33, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Suicidal Ideation; Suicide, Attempted; Treatment Outcome

2018

Other Studies

46 other study(ies) available for bupropion and paroxetine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
    Journal of medicinal chemistry, 2008, Jan-24, Volume: 51, Issue:2

    Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase

2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
    Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6

    Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:2

    Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution

2011
Species independence in brain tissue binding using brain homogenates.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7

    Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity

2011
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Paroxetine/bupropion combination treatment for refractory depression.
    Journal of clinical psychopharmacology, 1996, Volume: 16, Issue:1

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Drug Resistance; Drug Therapy, Combination; Female; Humans; Middle Aged; Paroxetine

1996
Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
    Clinical pharmacology and therapeutics, 1997, Volume: 61, Issue:4

    Topics: 1-Naphthylamine; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Bupropion; Dopamine Uptake Inhibitors; Female; Fluoxetine; Humans; Male; Middle Aged; Orgasm; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Surveys and Questionnaires

1997
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1997, Volume: 9, Issue:4

    Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Bupropion; Drug Therapy, Combination; Female; Fluoxetine; Humans; Libido; Male; Middle Aged; Mood Disorders; Pain Measurement; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome

1997
Evaluating the tolerability of the newer antidepressants.
    The Journal of nervous and mental disease, 1999, Volume: 187, Issue:2

    Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride

1999
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
    Drug metabolism and disposition: the biological fate of chemicals, 2000, Volume: 28, Issue:10

    Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles

2000
Re: Managing depression refractory to SSRIs.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2000, Volume: 45, Issue:9

    Topics: Adult; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Paroxetine; Treatment Outcome

2000
Type II error and antidepressants.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:5

    Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Delayed-Action Preparations; Depressive Disorder; Drug Therapy, Combination; False Negative Reactions; Humans; Paroxetine; Patient Selection; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Recurrence; Research Design; Treatment Outcome

2001
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2002, Volume: 47, Issue:2

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride

2002
Combined antidepressant treatment: a risk factor for switching in bipolar patients.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:4

    Topics: Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Bupropion; Carbamazepine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Middle Aged; Paroxetine; Risk Factors; Treatment Outcome

2002
Risk factors for falls during treatment of late-life depression.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:10

    Topics: Accidental Falls; Age Factors; Aged; Antidepressive Agents; Blood Pressure; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Hypotension, Orthostatic; Male; Multivariate Analysis; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Psychotherapy; Risk Factors; Selective Serotonin Reuptake Inhibitors; Survival Analysis

2002
Antidepressant-like effects in various mice strains in the tail suspension test.
    Behavioural brain research, 2003, Aug-14, Volume: 143, Issue:2

    Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Bupropion; Citalopram; Depression; Desipramine; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Hindlimb Suspension; Imipramine; Male; Mice; Mice, Inbred Strains; Paroxetine; Selective Serotonin Reuptake Inhibitors; Species Specificity

2003
Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma.
    Medical hypotheses, 2004, Volume: 62, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bupropion; Chemotherapy, Adjuvant; Dibenzothiazepines; Evidence-Based Medicine; Humans; Multiple Myeloma; Paroxetine; Quetiapine Fumarate; Treatment Outcome

2004
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
    Consumer reports, 2004, Volume: 69, Issue:10

    Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work

2004
Recurrent paroxetine-induced hyponatremia.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2004, Volume: 49, Issue:11

    Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Paroxetine; Recurrence; Sodium Chloride

2004
Maintenance treatment of depression in old age.
    The New England journal of medicine, 2006, Jun-08, Volume: 354, Issue:23

    Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Paroxetine; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index

2006
Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.
    Pharmacopsychiatry, 2006, Volume: 39, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Fatigue Syndrome, Chronic; Female; Humans; Paroxetine; Psychiatric Status Rating Scales

2006
Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy.
    The American journal of psychiatry, 2007, Volume: 164, Issue:6

    Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Lithium Compounds; Male; Nortriptyline; Paroxetine; Psychotherapy; Secondary Prevention; Time Factors; Treatment Outcome

2007
Psychopharmacology news.
    Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:6

    Topics: Antidepressive Agents; Bupropion; Congresses as Topic; Dopamine Uptake Inhibitors; Drug Industry; Humans; Paroxetine; Randomized Controlled Trials as Topic; Smoking Prevention

2007
Model-based approach and signal detection theory to evaluate the performance of recruitment centers in clinical trials with antidepressant drugs.
    Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:3

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Depressive Disorder, Major; Double-Blind Method; Humans; Logistic Models; Multicenter Studies as Topic; Paroxetine; Patient Selection; Signal Detection, Psychological; Treatment Outcome

2008
Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Psychiatry research, 2008, Jul-15, Volume: 160, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Brief Psychiatric Rating Scale; Bupropion; Cognition Disorders; Delayed-Action Preparations; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Neuropsychological Tests; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome

2008
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
    Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:3

    Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Nortriptyline; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sex Factors

2009
When is a "generic" medication not really a generic?
    Journal of psychosocial nursing and mental health services, 2010, Volume: 48, Issue:2

    Topics: Bupropion; Cyclohexanols; Drug Costs; Drug Labeling; Drug Prescriptions; Drugs, Generic; Humans; Marketing of Health Services; Paroxetine; Patient Selection; Psychiatric Nursing; Psychotropic Drugs; Therapeutic Equivalency; United States; United States Food and Drug Administration; Valproic Acid; Venlafaxine Hydrochloride

2010
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2010, Volume: 55, Issue:3

    Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Bupropion; Combined Modality Therapy; Comorbidity; Database Management Systems; Humans; Inositol; Lamotrigine; Multicenter Studies as Topic; Paroxetine; Psychotherapy, Brief; Randomized Controlled Trials as Topic; Recurrence; Research Design; Risperidone; Smoking; Substance-Related Disorders; Suicide; Treatment Outcome; Triazines; United States; Vitamin B Complex

2010
A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion.
    Journal of clinical anesthesia, 2012, Volume: 24, Issue:3

    Topics: Aged; Analgesics, Opioid; Anesthesia, General; Bupropion; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Fentanyl; Humans; Mastectomy; Ondansetron; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Thiophenes

2012
Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task.
    Journal of psychopharmacology (Oxford, England), 2013, Volume: 27, Issue:2

    Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Choice Behavior; Cyclobutanes; Cyclohexanols; Fluoxetine; Hypnotics and Sedatives; Idazoxan; Impulsive Behavior; Male; Norepinephrine; Paroxetine; Rats; Reaction Time; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride

2013
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
    Molecular neurodegeneration, 2013, Apr-26, Volume: 8

    Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion; Disease Models, Animal; Immunohistochemistry; Levodopa; Mood Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Rats; Rats, Wistar

2013
Restoration of serotonin neuronal firing following long-term administration of bupropion but not paroxetine in olfactory bulbectomized rats.
    The international journal of neuropsychopharmacology, 2014, Oct-31, Volume: 18, Issue:4

    Topics: Action Potentials; Animals; Antidepressive Agents, Second-Generation; Bupropion; CA3 Region, Hippocampal; Depressive Disorder, Major; Disease Models, Animal; Dorsal Raphe Nucleus; Locus Coeruleus; Male; Olfactory Bulb; Paroxetine; Piperazines; Pyramidal Cells; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonergic Neurons; Serotonin Antagonists; Ventral Tegmental Area

2014
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
    Journal of affective disorders, 2015, Jul-15, Volume: 180

    Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Moclobemide; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome

2015
Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.
    Journal of neural transmission (Vienna, Austria : 1996), 2017, Volume: 124, Issue:3

    Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain; Bupropion; Chromatography, High Pressure Liquid; Cyclopropanes; Depressive Disorder; Desipramine; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Piperidines; Receptors, N-Methyl-D-Aspartate

2017
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:4

    Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pharmacoepidemiology; Sertraline; United States; Venlafaxine Hydrochloride

2018
The effect of paroxetine, venlafaxine and bupropion administration alone and combined on spatial and aversive memory performance in rats.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:6

    Topics: Animals; Antidepressive Agents; Avoidance Learning; Bupropion; Drug Therapy, Combination; Male; Maze Learning; Memory Disorders; Paroxetine; Rats; Rats, Wistar; Spatial Memory; Venlafaxine Hydrochloride

2018
Effects of long-term paroxetine or bupropion treatment on puberty onset, reproductive and feeding parameters in adolescent male rats.
    Andrologia, 2019, Volume: 51, Issue:6

    Topics: Adolescent; Animals; Antidepressive Agents; Bupropion; Fertility; Humans; Male; Models, Animal; Paroxetine; Rats; Rats, Sprague-Dawley; Sexual Maturation; Sperm Motility; Spermatozoa; Testis; Time Factors

2019
Chronic exposure to paroxetine or bupropion modulates the pubertal maturation and the reproductive system in female rats.
    Reproductive biology, 2020, Volume: 20, Issue:2

    Topics: Animals; Anti-Mullerian Hormone; Antidepressive Agents, Second-Generation; Bupropion; Eating; Estradiol; Female; Genitalia; Luteinizing Hormone; Organ Size; Ovary; Paroxetine; Rats; Rats, Sprague-Dawley; Sexual Maturation; Uterus

2020
Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:10

    Topics: Antidepressive Agents; Atenolol; Bisoprolol; Bupropion; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Prescriptions; Fluoxetine; Humans; Metoprolol; Paroxetine; Retrospective Studies

2022